000136713 001__ 136713
000136713 005__ 20240229105054.0
000136713 0247_ $$2doi$$a10.1007/s11307-017-1155-x
000136713 0247_ $$2pmid$$apmid:29270848
000136713 0247_ $$2ISSN$$a1536-1632
000136713 0247_ $$2ISSN$$a1860-2002
000136713 0247_ $$2altmetric$$aaltmetric:31914271
000136713 037__ $$aDKFZ-2018-01151
000136713 041__ $$aeng
000136713 082__ $$a610
000136713 1001_ $$aFlechsig, Paul$$b0
000136713 245__ $$aRole of CT Density in PET/CT-Based Assessment of Lymphoma.
000136713 260__ $$aAmsterdam [u.a.]$$bElsevier Science$$c2018
000136713 3367_ $$2DRIVER$$aarticle
000136713 3367_ $$2DataCite$$aOutput Types/Journal article
000136713 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1536316532_14253
000136713 3367_ $$2BibTeX$$aARTICLE
000136713 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000136713 3367_ $$00$$2EndNote$$aJournal Article
000136713 520__ $$aIn patients with Hodgkin (HL) and non-Hodgkin lymphoma (NHL), primary staging, as well as intermediate and late response assessment, is often performed by integrated 2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG) positron emission tomography/X-ray computed tomography (PET/CT). The purpose of this analysis was to evaluate if findings in patients with histopathologically proven HL or NHL might correlate with semi-automated density measurements of target lesions (TLs) in the CT component of the integrated PET/CT examination.After approval by the institutional review board, 176 lymph nodes (LN) in 90 PET/CT examinations of 90 patients were retrospectively analyzed (HL, 108 TLs out of 55 patients; NHL, 68 TLs out of 35 patients). PET/CT was performed for reasons of primary staging, response evaluation as interim PET, or as final examination after therapy, according to the clinical schedule. Analyses of TLs were performed on the basis of tracer uptake (SUV) 60 min after tracer injection and volumetric CT histogram analysis in non-contrast-enhanced CT.All patients were diagnosed with HL or NHL in a pretreatment biopsy. Prior to therapy induction, staging of all patients was performed using contrast-enhanced CT of the neck to the pelvis, or by [18F]FDG PET/CT. Of the 176 TLs, 119 were classified as malignant, and 57 were benign. Malignant TLs had significantly higher CT density values compared to benign (p < 0.01).Density measurements of TLs in patients with HL and NHL correlate with the dignity of TLs and might therefore serve as a complementary surrogate parameter for the differentiation between malignant and benign TLs. A possible density threshold in clinical routine might be a 20-Hounsfield units (HU) cutoff value to rule out benignancy in TLs that are above the 20-HU threshold.
000136713 536__ $$0G:(DE-HGF)POF3-315$$a315 - Imaging and radiooncology (POF3-315)$$cPOF3-315$$fPOF III$$x0
000136713 588__ $$aDataset connected to CrossRef, PubMed,
000136713 7001_ $$aWalker, Christina$$b1
000136713 7001_ $$aKratochwil, Clemens$$b2
000136713 7001_ $$aKönig, Laila$$b3
000136713 7001_ $$aIagura, Andrei$$b4
000136713 7001_ $$aMoltz, Jan$$b5
000136713 7001_ $$0P:(DE-He78)457c042884c901eb0a02c18bb1d30103$$aHolland-Letz, Tim$$b6$$udkfz
000136713 7001_ $$aKauczor, Hans-Ulrich$$b7
000136713 7001_ $$0P:(DE-He78)13a0afba029f5f64dc18b25ef7499558$$aHaberkorn, Uwe$$b8
000136713 7001_ $$0P:(DE-He78)5ca7e97b2769bb97f8c73431c6566b94$$aGiesel, Frederik$$b9$$eLast author
000136713 773__ $$0PERI:(DE-600)2079211-6$$a10.1007/s11307-017-1155-x$$gVol. 20, no. 4, p. 641 - 649$$n4$$p641 - 649$$tMolecular imaging & biology$$v20$$x1860-2002$$y2018
000136713 909CO $$ooai:inrepo02.dkfz.de:136713$$pVDB
000136713 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)457c042884c901eb0a02c18bb1d30103$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000136713 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)13a0afba029f5f64dc18b25ef7499558$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000136713 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)5ca7e97b2769bb97f8c73431c6566b94$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000136713 9131_ $$0G:(DE-HGF)POF3-315$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImaging and radiooncology$$x0
000136713 9141_ $$y2018
000136713 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000136713 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000136713 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bMOL IMAGING BIOL : 2015
000136713 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000136713 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000136713 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000136713 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000136713 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000136713 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000136713 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000136713 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000136713 9201_ $$0I:(DE-He78)E060-20160331$$kE060$$lKKE Nuklearmedizin$$x0
000136713 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lBiostatistik$$x1
000136713 980__ $$ajournal
000136713 980__ $$aVDB
000136713 980__ $$aI:(DE-He78)E060-20160331
000136713 980__ $$aI:(DE-He78)C060-20160331
000136713 980__ $$aUNRESTRICTED